

# Form Title Perinatal HIV Prevention for Unknown HIV Status and High Risk Adult Inpatient Order Set

Form Number 21801-bond

© 2018, Alberta Health Services, CKCM



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-nd/4.0/

**Disclaimer:** This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.



# Perinatal HIV Prevention for Unknown HIV Status and High Risk Adult Inpatient Order Set

Select orders by placing a ( $\checkmark$ ) in the associated box

Last Name (Legal)		First Name (Legal)		
Preferred Name □ L	ame 🗆 Last 🗆 First		DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender  Male Female Non-binary/Prefer not to disclose (X) Unknown				

Initiate this treatment plan when one or more of the following has occurred:

- Rupture of membranes
- Onset of labour (greater than 3 cm dilated)
- Greater than or equal to 3 hours prior to planned Caesarian section
- In any other situation where delivery is anticipated

#### General

Management of labour:

- Routine practices apply (mask, gown, eye protection, double gloves)
- · No artificial rupture of membranes unless absolutely necessary for obstetrical management
- Rupture of membranes greater than 4 hours should be avoided if possible
- Avoid the use of fetal scalp electrodes, fetal scalp sampling, intrauterine pressure catheters, and forceps/vacuumassisted delivery unless benefits exceed risks

Where maternal HIV status is unknown (no antenatal HIV test result or ongoing high risk of HIV exposure since last negative test).

#### Patient Care

Clinical Communication– Ensure that patient consent for HIV testing has been obtained and documented.

### Laboratory Investigations STAT

#### Hematology

□ CBC with differential STAT

#### Chemistry

- □ Alanine Amino Transferase (ALT) STAT
- □ Creatinine STAT
- □ Glucose, Random STAT
- □ Bilirubin, Total STAT

#### Immunology

Page Virologist on call for either Northern or Southern Alberta as appropriate

- □ HIV 1 and 2 Serology (Antigen and Antibody) STAT. The prescriber who orders this test is obliged to report a positive result to the Medical Office of Health.
- □ Hepatitis B surface antigen (HBsAG) STAT
- □ Hepatitis C antibody (HCV Ab) STAT

□ Syphilis EIA

If indicated (unknown HIV status, or ongoing risk)

- □ HIV 1 and 2 Serology (Antigen and Antibody) RAPID
- □ HIV RNA PCR STAT (collect 3 mLs per tube in each of TWO lavender topped {EDTA} tubes). Will be processed only if HIV antibody test is positive.)

Prescriber Name	Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh:mm)



# Perinatal HIV Prevention for Unknown HIV Status and High Risk Adult Inpatient Order Set

Last Name (Legal)		First Name (Legal)		
Preferred Name   Last  First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender       □ Male       □ Female         □Non-binary/Prefer not to disclose (X)       □ Unknown				

$\mathbf{O}_{\mathbf{A}}$ is the end of the state of $\mathbf{A}$ in the end of the distribution	Administrative Gender U Male U Female		
Select orders by placing a ( $\checkmark$ ) in the associated box	□Non-binary/Prefer not to disclose (X) □ Unknown		
Fluids and Electrolytes			
IV Maintenance			
Intravenous cannula – Insert IV			
IV Fluid Boluses			
□ Lactated Ringer's infusion mL IV over			
□ sodium chloride 0.9% infusion mL IV ove	r minutes		
IV Fluid Infusions			
□ sodium chloride 0.9% infusion at mL/hou			
□ dextrose 5%-sodium chloride 0.9% infusion at			
dextrose 5%-sodium chloride 0.45% infusion at	mL/hour		
Medications			
Anti-Infective Agents If labour stops and infusion is discontinued for greater than 6 h	nours, re-administer zidovudine loading dose and resume		
continuous infusion when labour re-commences.			
□ zidovudine (AZT, ZDV, RETROVIR) in NaCl 0.9% (4 n	ng/mL zidovudine) bag, administer 2 mg/kg IV over 1		
hour as a loading dose			
THEN			
zidovudine IV continuous infusion 1 mg/kg per hour un	ntil the umbilical cord is clamped		
THEN			
Discontinue zidovudine IV at the time of clamping of u	mbilical cord		
Patient Care			
□ Breastfeeding is not recommended pending HIV resul	ts		
Medications			
Central Nervous System Agents			
Review for contraindications and discuss implications with path	ient before prescribing for lactation suppression		
□ cabergoline 1 mg PO once, on first post-partum day			
Hormones			
Review with patient and offer injectable contraception pri	-		
medroxyPROGESTERone acetate (Depo-Provera) 150 mg IM once on the day of discharge from hospital or 5th post-partum day (whichever comes first). Indication: Contraception.			
Consults/Referrals			
Inpatient Specialty Consults			
□ Infectious Disease Consult. MRHP to consider in-person regarding suspected HIV seroconversion, new diagnosis of			
Clinical Communication to Nurse – If diagnosis of HIV is confir	med, refer to Northern Alberta Program ( NAP ) or		
Southern Alberta Clinic (SAC) as soon as the diagnosis of HI	÷ , ,		

discharge to arrange follow up.

Prescriber Name	Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh:mm)